Dihexa: Complete Research Guide & Chemical Profile

Dihexa (systematic name: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a small peptidomimetic compound derived from the angiotensin IV hexapeptide Val-Tyr-Ile-His-Pro-Phe. It was developed at Washington State University by the research group of Joseph Harding and John Wright as part of a systematic structure-activity campaign to create metabolically stable analogs of the AT4 receptor ligand Nle1-angiotensin IV (Norleual). Its molecular formula is C₂₇H₄₃N₃O₅ with a molecular weight of approximately 587.6 Da.

The compound retains the central Tyr-Ile dipeptide core of angiotensin IV but replaces the N-terminal Val with a hexanoic acid cap and the C-terminal His-Pro-Phe with a 6-aminohexanoic amide moiety. These modifications dramatically improve metabolic stability by eliminating peptidase-susceptible bonds while preserving the spatial orientation of key pharmacophoric elements. The relatively low molecular weight and balanced lipophilicity contribute to oral bioavailability, which is unusual among peptide-derived compounds.

• Systematic Name: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide
• Molecular Formula: C₂₇H₄₃N₃O₅
• Molecular Weight: ~587.6 Da
• Class: Peptidomimetic (angiotensin IV analog)
• Origin: Washington State University (Harding/Wright laboratory)
• Key Feature: Oral bioavailability in preclinical models
• Solubility: Soluble in DMSO, ethanol; limited aqueous solubility at neutral pH
• Storage: -20°C, protected from light and moisture

Dihexa emerged from decades of research on angiotensin IV (Ang IV, Val-Tyr-Ile-His-Pro-Phe), a hexapeptide fragment of the renin-angiotensin system that enhances cognitive function in animal models. Ang IV was initially reported to bind the AT4 receptor, later identified as insulin-regulated aminopeptidase (IRAP). However, subsequent research from the Harding group proposed that the cognitive effects of Ang IV analogs operate through a distinct mechanism involving the hepatocyte growth factor (HGF)/c-Met receptor system rather than through IRAP inhibition alone.

The development pathway proceeded from Ang IV through Norleual (Nle1-Ang IV, replacing Val1 with norleucine for metabolic stability), then to progressively simplified analogs that retained cognitive-enhancing activity while improving drug-like properties. Dihexa represents the culmination of this optimization: a minimal pharmacophore with dramatically enhanced potency (picomolar vs micromolar for Ang IV), oral activity, and resistance to enzymatic degradation.

This development trajectory illustrates the peptidomimetic approach to peptide drug design, where systematic truncation and non-natural substitutions convert a metabolically labile peptide into a stable small molecule that retains the biological activity of the parent compound. The result is a compound that bridges the gap between peptide pharmacology and conventional small-molecule drug characteristics.

The proposed primary mechanism of Dihexa involves potentiation of the hepatocyte growth factor (HGF)/c-Met receptor tyrosine kinase system. Research from the Harding laboratory demonstrated that Dihexa binds to HGF and facilitates its dimerization, which is a prerequisite for high-affinity binding to c-Met and subsequent receptor activation. This mechanism amplifies endogenous HGF signaling rather than constitutively activating c-Met, making the response dependent on ambient HGF concentrations.

c-Met activation triggers multiple downstream signaling cascades relevant to neuronal function: the PI3K/Akt pathway (promoting cell survival and growth), the Ras/MAPK/ERK pathway (stimulating cell proliferation and differentiation), and the STAT3 pathway (transcriptional regulation). In neurons, these pathways converge on processes essential for synaptic plasticity including dendritic spine formation, receptor trafficking, and long-term potentiation (LTP) maintenance.

HGF/c-Met signaling plays established roles in brain development, neuronal survival, and synaptic plasticity. HGF is expressed in hippocampal and cortical neurons, and c-Met is present on both neurons and glia. Genetic studies in mice have shown that disruption of HGF/c-Met signaling impairs hippocampal-dependent learning and memory. Dihexa is proposed to augment this endogenous neurotrophic system at concentrations several orders of magnitude below those required for the parent compound Ang IV.

Preclinical studies from the originating laboratory reported that Dihexa enhances cognitive performance in multiple behavioral paradigms. In the Morris water maze spatial memory task, Dihexa-treated animals demonstrated faster acquisition and stronger retention of the platform location. Similar improvements were observed in novel object recognition and spontaneous alternation tasks, suggesting effects on both spatial and non-spatial memory processes.

A key finding was that Dihexa promotes spinogenesis — the formation of new dendritic spines — in hippocampal neuron cultures. Dendritic spines are the primary postsynaptic structures for excitatory synapses, and their formation and stabilization are considered structural correlates of learning and memory. Dihexa was reported to increase spine density at picomolar concentrations, with an inverted U-shaped concentration-response curve suggesting optimal activity within a narrow concentration window.

The compound has been investigated in models of cognitive impairment including scopolamine-induced amnesia (a cholinergic deficit model) and age-related cognitive decline. In these paradigms, Dihexa restored performance to levels comparable to young or non-impaired controls. These findings are interpreted in the context of HGF/c-Met-mediated synaptogenesis compensating for synaptic loss, though the complete mechanism requires further investigation across independent research groups.

Beyond synaptogenesis, Dihexa has demonstrated neurotrophic activity in neuronal cell culture systems. The compound promoted neurite outgrowth in hippocampal neurons and enhanced neuronal survival under conditions of trophic factor withdrawal. These effects are consistent with HGF/c-Met activation, as HGF is an established neurotrophic factor that supports neuronal differentiation, axon guidance, and survival during development and after injury.

In organotypic hippocampal slice cultures, Dihexa application enhanced the maintenance of LTP (long-term potentiation), the electrophysiological correlate of synaptic strengthening that underlies learning and memory at the cellular level. LTP enhancement was blocked by the c-Met inhibitor SU11274, providing pharmacological evidence that the synaptic effects are mediated through the HGF/c-Met pathway. This receptor-dependence distinguishes Dihexa from non-specific neurostimulants.

It should be noted that the majority of published Dihexa research originates from a single laboratory, and independent replication by other research groups is essential for establishing the robustness and generalizability of these findings. The specificity of HGF/c-Met engagement and the picomolar potency claims warrant particular scrutiny through independent experimental validation.

One of the most notable properties of Dihexa is its reported oral bioavailability, which is unusual for peptide-derived compounds. The low molecular weight (~587 Da), moderate lipophilicity, and absence of traditional peptide bonds susceptible to GI tract peptidases contribute to favorable oral absorption. Preclinical studies demonstrated that oral administration produced cognitive-enhancing effects comparable to parenteral routes, suggesting sufficient CNS exposure after oral dosing.

The compound satisfies most of Lipinski rule-of-five criteria for oral drug candidates: molecular weight below 500 Da is marginally exceeded, but the hydrogen bond donor/acceptor counts and calculated logP fall within acceptable ranges. Blood-brain barrier penetration has been inferred from pharmacological activity after systemic administration, though direct measurement of brain concentrations and detailed pharmacokinetic parameters (clearance, volume of distribution, half-life) have not been extensively published.

The SAR studies leading to Dihexa revealed several critical structural requirements for HGF-potentiating activity. The Tyr-Ile dipeptide core is essential and cannot be substituted without loss of activity. The N-terminal hexanoyl cap provides optimal hydrophobic character; shorter (butanoyl) or longer (octanoyl) acyl chains reduce potency. The C-terminal 6-aminohexanoic amide spacer provides the correct distance between the dipeptide core and the terminal amide.

• Tyr-Ile dipeptide: Essential pharmacophore, cannot be substituted
• N-hexanoyl cap: Optimal chain length; shorter or longer chains reduce potency
• 6-aminohexanoic amide: Correct spacer length; 4- or 8-carbon chains less active
• C-terminal amide: Required for full activity; free acid shows reduced potency
• D-amino acid substitutions: Not tolerated at either Tyr or Ile positions
• Tyr hydroxyl group: Essential for activity, suggesting hydrogen bonding role

These SAR findings support a model in which Dihexa occupies a specific binding site on the HGF molecule that facilitates the conformational change required for HGF dimerization and high-affinity c-Met engagement. The strict structural requirements argue against non-specific membrane effects and support a defined molecular target interaction.

Dihexa is supplied as a white to off-white powder and is stable for 24 months at -20°C when protected from light, moisture, and atmospheric oxygen. Unlike conventional peptides, the absence of traditional peptide bonds in the backbone confers significant resistance to enzymatic degradation. However, the tyrosine hydroxyl group is susceptible to oxidation, and storage under inert gas is recommended.

The compound has limited aqueous solubility at neutral pH. For research applications, Dihexa is first dissolved in DMSO to create a concentrated stock solution (typically 10-50 mM), which is then diluted into aqueous buffer to the desired working concentration. The final DMSO concentration in experimental solutions should be kept below 0.1% to avoid solvent effects on biological systems. Alternatively, dissolution in ethanol followed by aqueous dilution is acceptable for some applications.

• Lyophilized storage: -20°C, protected from light, 24 months
• Primary solvent: DMSO (stock solution at 10-50 mM)
• Dilution: Aqueous buffer; keep DMSO <0.1% final concentration
• Alternative: Dissolve in ethanol, then dilute to aqueous
• Reconstituted DMSO stocks: -20°C, stable for 6 months
• Avoid repeated freeze-thaw; aliquot into single-use volumes
• Protect from light due to tyrosine oxidation sensitivity

Identity verification of Dihexa by mass spectrometry should confirm [M+H]⁺ at m/z ~588.6 by ESI-MS. The relatively low molecular weight produces a simple mass spectrum dominated by the singly charged protonated species. High-resolution mass spectrometry (HRMS) can distinguish Dihexa from isobaric compounds with mass accuracy below 5 ppm, providing definitive identity confirmation.

HPLC purity assessment using a C18 column with acetonitrile/water gradient containing 0.1% TFA or formic acid should yield a single dominant peak. Research-grade Dihexa should demonstrate ≥98% purity by HPLC area normalization. UV detection at 214 nm (amide absorption) and 280 nm (tyrosine absorption) provides dual-wavelength confirmation. The tyrosine chromophore also enables concentration determination by UV spectrophotometry using the extinction coefficient at 280 nm.

The following publications provide the primary research basis for understanding Dihexa. Researchers should note that much of the published data originates from the originating laboratory and independent replication is encouraged.

• Read more: TRH (Thyrotropin-Releasing Hormone): Research Guide & Chemical Profile → https://www.chemverify.com/learn/trh-thyrotropin-releasing-hormone-research-guide
• Read more: Ipamorelin + CJC-1295 (No DAC) Stack: Synergy Research Guide → https://www.chemverify.com/learn/ipamorelin-cjc-1295-no-dac-stack-synergy
• Read more: TP508 (Chrysalin): Research Guide & Chemical Profile → https://www.chemverify.com/learn/tp508-chrysalin-research-guide-chemical-profile
• Read more: Semax for Cognitive Research: ACTH(4-10) Analog Mechanism → https://www.chemverify.com/learn/semax-cognitive-research-acth-mechanism